Adults with newly diagnosed acute myeloid leukemia or AML who:
A study of ASP2215 (gilteritinib) by itself, ASP2215 combined with azacitidine or azacitidine by itself to treat adult patients who have recently been diagnosed with acute myeloid leukemia with a FLT3 gene mutation and who cannot receive standard chemotherapy
Keep in mind that people who are in the study may choose to stop at any time.
Being part of a clinical trial takes time and effort for people in it and their caregivers. Here is important information you should know about the LACEWING clinical trial:
Up to 7
Being part of the LACEWING clinical trial takes time and effort for the person in it and their caregiver. You may:
This medicine is experimental. Because of that, the effectiveness has not been established and not all risks are known before starting the clinical trial. Furthermore, you may experience side effects from the clinical trial treatment. People who are in the study may choose to stop at any time.
This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster. For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza®) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster. This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine. There is a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.
Based on your answers, you may be a good fit for this study.
A study doctor at the clinical trial center will determine
if you qualify for the study.
To learn more about being in the study, contact a clinical trial center.
To find the clinical trial center closest to you, enter your location below.
Based on your answers, this study may not be right for you. Please talk to your doctor if you still have questions about the LACEWING study. Or, if you still think you may be a good fit for this clinical trial, search below for a clinical trial center near you. You can contact the doctor who is leading the study and speak with them.